FDA Panel Supports Peptide Therapies Amid Regulatory Uncertainty
A panel advising the Food and Drug Administration (FDA) has voted to support the production of six out of seven peptide therapies, despite concerns from FDA scientists. These peptides, including BPC-157 and TB-500, are popular in wellness circles for their potential benefits in injury recovery and muscle growth. However, they remain illegal for U.S. pharmacies to produce. The FDA must now decide whether to allow compounding pharmacies to manufacture these peptides, a decision that could significantly impact their availability and regulation. 
